Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt...
Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway
About this item
Full title
Author / Creator
Zhang, Ye , Lu, Peng , Zhou, Yan and Zhang, Lifei
Publisher
United States: PeerJ. Ltd
Journal title
Language
English
Formats
Publication information
Publisher
United States: PeerJ. Ltd
Subjects
More information
Scope and Contents
Contents
Ibrutinib, a bruton tyrosine kinase (BTK) inhibitor which suppresses B-cell receptor signaling, has remarkably improved the outcome of patients with mantle cell lymphoma (MCL). However, approximately 33% of MCL patients have primary Ibrutinib resistance, and acquired Ibrutinib resistance is nearly universal. Long intergenic non-coding RNA for kinas...
Alternative Titles
Full title
Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b4da6715f13b4ac7b04424b7d675dfed
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b4da6715f13b4ac7b04424b7d675dfed
Other Identifiers
ISSN
2167-8359
E-ISSN
2167-8359
DOI
10.7717/peerj.12571
